Estradiol supplementation has been shown to enhance cognitive performance in old ovariectomized rhesus macaques (Macaca mulatta). To determine if similar benefits could be achieved in perimenopausal animals using alternative hormonal supplements, we administered dehydroepiandrosterone (DHEA) to old ovary-intact female rhesus macaques for ∼2.5 months. Using computerized touch screen memory tasks, including delayed response (DR) and delayed matching-to-sample (DMS), we observed improved performance with time in all of the animals but failed to detect a significant effect of DHEA. On the other hand, gene expression profiling disclosed a significant correlation between cognitive performance and the expression of several steroidogenic and steroid-responsive genes. The DR performance was positively correlated with hippocampal expression of AKR1C3 and STAR and negatively correlated with the expression of SDRD5A1. A positive correlation was also found between DMS performance and prefrontal cortical expression of AKR1C3 and a negative correlation with STAR, as well as a negative correlation with the hippocampal expression of HSD11B1 and NR3C1. Taken together, the results suggest that steroidogenic gene regulation within the brain may help to maintain cognitive function during the perimenopausal transition period, despite a decline in sex-steroid levels in the circulation.
Like women, old female rhesus macaques show a marked decline in circulating levels of estradiol (E 2 ) (Downs & Urbanski 2006; Gilardi et al. 1997) and this hormonal change is thought to exacerbate many age-associated physiological changes including cognitive decline (LeBlanc et al. 2001; Maki & Hogervorst 2003; Roberts et al. 1997; Sherwin 2006) . Not surprisingly, therefore, studies performed in ovariectomized female rhesus macaques have mostly reported significant improvements in memory after E 2 supplementation (Baxter et al. 2013; Lacreuse 2006; Lacreuse et al. 2002; Rapp et al. 2003a; Kohama et al. 2016; Tinkler & Voytko 2005; Voytko 2000; Voytko et al. 2008) . However, few studies have examined the therapeutic potential of other steroid hormones, especially those that serve as precursors for estrogen synthesis in the brain. For example, young adult rhesus macaques and humans both show high concentrations of the adrenal hormone dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), in their circulations. In addition, the hippocampus (HPC) expresses genes that encode key enzymes in the intracrine conversion of DHEA to E 2 (Sorwell et al. 2012) . In theory, therefore, rhesus macaques and humans have the potential to maintain elevated E 2 concentrations in cognitive brain areas, even when ovarian-derived E 2 levels in the circulation have been significantly attenuated, such as after menopause or as a result of ovariectomy. Unfortunately, the circulating levels of DHEA and DHEAS also decrease markedly during aging (Downs et al. 2008; Labrie et al. 1998 Labrie et al. , 2007 Rainey et al. 2002; Sorwell & Urbanski 2010; Sorwell et al. 2012 Sorwell et al. , 2014 Urbanski et al. 2013 ), suggesting that endogenous levels of DHEA and DHEAS in the elderly may be too low to serve as effective precursors for estrogen synthesis in the brain. On the other hand, this raises the issue of whether daily supplementation with exogenous DHEA can increase brain estrogen levels sufficiently to have therapeutic potential for age-associated cognitive decline, while avoiding negative side-effects associated with continuously elevated estrogen levels in the circulation.
Dehydroepiandrosterone is available in the USA without prescription, as a food supplement, and is already widely used by the elderly for self-medication (Wold et al. 2005) . However, the efficacy of DHEA supplementation on improving cognitive function in humans remains unproven, with the majority of clinical studies failing to show any significant beneficial effect (Davis et al. 2008 (Davis et al. , 2011 Grimley Evans et al. 2006; Scheffers et al. 2015) . Therefore, the goals of the present study were twofold: (1) to examine the pro-cognitive effects of DHEA supplementation in perimenopausal female rhesus macaques, taking advantage of the highly controlled environmental conditions under which these animals are maintained and (2) to gain insights into the underlying mechanism, by correlating cognitive performance with steroidogenic gene expression in cognitive centers of the brain. We hypothesized that supplementing perimenopausal females with physiological levels of DHEA would result in significant intracrine conversion of DHEA to E 2 in cognitive brain centers and thereby compensate for the perimenopausal decline in estrogen production by the ovaries. Consequently, we expected to observe significantly better cognitive performance in animals while undergoing DHEA supplementation. However, our results failed to support this hypothesis; instead, they support the existence of an alternate neuroendocrine mechanism in the HPC and prefrontal cortex (PFC) that may help to maintain cognitive function during the menopausal transition period.
Materials and methods

Experimental animals
This study was performed with approval from the OHSU Institutional Animal Care and Use Committee at the Oregon National Primate Research Center (ONPRC), using female rhesus macaques (Macaca mulatta). The animals were housed indoors under controlled environmental conditions: 24 ∘ C temperature; 12-h light and 12-h dark photoperiods (lights on at 0700 h). 
Characterization of hormonal status and DHEA supplementation
Eight old females (mean ± SEM age: 23.2 ± 0.44 years) were trained for unsedated blood collection. At the start of the study, they showed the following mean (±SEM) serum hormone levels: anti-Müllerian hormone (AMH) = 1.55 ± 0.56 ng/ml; follicle-stimulating hormone (FSH) = 1.35 ng/ml; DHEAS = 28.8 ± 4.38 ng/ml. All of these hormonal levels are consistent with animals starting their transition into perimenopause (Downs & Urbanski 2006; Sorwell et al. 2012) , which was corroborated by half of the animals already showing irregular menstrual cycles or complete acyclicity before the start of the cognitive testing. Preliminary tests found this administration paradigm to mimic the youthful circulatory patterns of DHEAS, characterized by daily morning peaks generally in the range of 160-400 ng/ml for 1-2 h after DHEA administration. Consequently, the animals each received 5 mg of oral DHEA inside a marshmallow treat, daily at 0745 h for ∼2.5 months.
Behavioral testing apparatus
Training and testing on behavioral tasks were performed in sound-insulated computerized behavioral testing chambers. Each chamber consisted of a modified cage (24 ′′ L × 24 ′′ W × 32 ′′ H) with 3 ′′ -spaced bars in the front to allow access to a 17 ′′ Elo-Touch Systems CRT Touchmonitor (Menlo Park, CA, USA). Chambers were also equipped with a light, two fans and a 1 ′′ closed-circuit video camera to allow for unobtrusive monitoring of behavior. During training and testing, animals remained unrestrained with full access to the touch screen. Food rewards were delivered into a rubber food receptacle in front of the touch screen by either a Med Associates (Fairfax, VT, USA) mini M&M candy dispenser or a custom-built universal food dispenser mounted on the top of the testing chambers. These food rewards were chosen based on individual animals' preferences and generally consisted of a mixture of candy, nuts and dried fruit. Animals were not strictly food-restricted; however, training and testing were performed in the morning after an overnight fast. The morning meal was provided immediately after the training/testing session. In the DMS task, monkeys were shown a picture at the center of a touch screen in the stimulus presentation phase (c) and, after a delay, were required to select the previously shown image in the query phase (d). Correct responses resulted in a small palatable food reward.
Task stimulus presentation and reward contingencies were controlled individually for each chamber by a suite of custom programs written in True Basic (Gold edition, True Basic Inc, Hartford, VT, USA) and run on Macintosh iMac computers (Apple Inc, Cupertino, CA, USA).
Cognitive training and testing
A detailed outline of the cognitive testing schedule is shown in Fig. 1 . The animals were first trained to touch a physical target outside their home cage. Later, animals were acclimated to the testing chambers and trained to transfer the targeting response to the touch screen for manually controlled rewards. Once able to target the screen without assistance, they were placed on an automated training program and rewarded for hitting a large red square presented in random locations on the screen. The size of the square was gradually reduced until animals were able to hit a 3 ′′ × 3 ′′ square with 90% accuracy over 80 trials. They were then trained on the two tasks described below at successive delays of 1-5 seconds and were required to reach a criterion of 85% accuracy at the 5-second delay in each task before advancing to the testing battery.
In the delayed response (DR) task, the subject was presented with a red square on either the left or right side of the touch screen and acknowledged its presence by touching it (Fig. 1a) . After a variable delay (1, 5, 15 or 30 seconds, presented in random order), the subject was presented with two red squares, one on each side of the screen (Fig. 1b) . In the delayed matching-to-sample (DMS) task, the subject first acknowledged the presence of a clipart picture displayed in the center of the touch screen by touching it (Fig. 1c) . After a delay (5, 30, 60, 120 or 240 seconds, again presented in random order), the previously shown picture and a novel picture were displayed randomly on the left and right sides of the touch screen (Fig. 1d) . The subject indicated its selection by touching one of the two pictures. A correct response (selection of the square on the previously shown side in DR; selection of the previously shown image in DMS) was associated with a small palatable food reward delivered into a hopper in front of the screen, a positively conditioned auditory tone and a 1.5-second intertrial interval (ITI). An incorrect response resulted in no food reward, a negatively conditioned auditory tone and a 3-second ITI. Each testing battery consisted of 5 days of DR testing, with 20 trials/day at each of the four delays (total of 100 trials per delay) and 10 days of DMS testing, with 10 trials/day at each delay (total of 100 trials per delay). In both tasks, the primary outcome measure was the percent correct responses at each delay across all testing days. While no images were repeated in the DMS task over the course of a single testing session, the same bank of images was accessed for each session, allowing for the potential repetition of images across testing days. The behavioral testing schedule is shown in Fig. 2 . An initial testing battery was completed before the start of DHEA administration, followed by testing batteries starting 1 week, 1 and 2 months after the start of DHEA administration. Additional testing batteries began 1 week, 1 and 2 months after the cessation of DHEA supplementation.
Statistical analysis of cognitive data
Scores for each cognitive battery were calculated as percent correct at each delay for 5 days of DR (50 trials per delay) and 10 days of DMS (100 trials per delay). To examine the effect of DHEA administration on cognitive performance, percent improvement in score from the first (baseline) battery test of each phase (on DHEA and off DHEA) to the third battery test was calculated. As roughly equivalent levels of improvement were seen within each phase of the study, this manipulation normalized performance to the beginning of each study phase and controlled for individual variation between animals. These improvement scores were analyzed using a repeated-measures analysis of variance (ANOVA), with treatment and delay as within-subjects factors. An additional repeated-measures ANOVA was performed with treatment and delay as within-subjects factors and hormonal status as a between-subjects factor. Where the assumption of sphericity was not met as determined by Mauchly's test of sphericity, the Greenhouse-Geisser was used as a correction. In all figures, data are presented as means ± SEM.
Serum hormone measurements
As previously reported (Downs & Urbanski 2006; Sorwell & Urbanski 2010; Sorwell et al. 2012) , AMH was assayed using a commercially available enzyme-linked immunosorbent assay kit (Diagnostic Systems Laboratories Inc., Webster, TX, USA), while FSH and DHEAS were measured by radioimmunoassay; the intra-assay coefficients of variation of these assays were <10%. Estradiol was assayed by electro-chemiluminescence using the Elecsys 2010 Platform (Roche Diagnostics, Indianapolis, IN, USA); the intra-assay coefficient of variation was <6% (Sorwell et al. 2012) .
Tissue processing and quantification of RNA Postmortem brain tissue was obtained from the eight old DHEA-supplemented animals, as described above. Total RNA was extracted from the HPC and dorsolateral PFCs using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and converted to complementary DNA using the RT 2 First Strand Kit (SABiosciences, Qiagen, Valencia, CA, USA). The samples were then run on custom RT 2 Profiler polymerase chain reaction Array plates (SABiosciences) in accordance with the kit instructions. Genes selected for inclusion on this plate were chosen for their involvement in either steroidogenesis [i.e. steroidogenic enzymes or transport proteins such as steroidogenic acute regulatory protein (StAR)] or steroid responses (i.e. steroid receptors and intracellular signaling proteins involved in the estrogen response). All genes were normalized against the arithmetic mean expression value of the three housekeeping genes: ALG9, GAPDH and RPL13A.
Correlation of cognitive performance with gene expression
To allow for correlations between gene expression and cognitive performance, animals were classified based on their scores on the 15-second delay in the DR task and the 60-second delay in the DMS task during the final testing battery. These specific delays were chosen as they showed the widest variability in performance among the animals. The final testing battery was chosen for analysis as this allowed animals to learn and practice the task as much as possible after meeting the baseline criteria. Animals were ranked based on their mean performance at this delay and ranks were correlated with gene expression using Kendall's b. The threshold level of significance was defined as = 0.05.
Results
Effect of DHEA supplementation on cognitive performance
As expected, in the DR task there was a significant within-subjects effect of delay (F 3,18 = 63.211, P < 0.001), showing that animals performed worse at longer delays (Fig. 3a) . Similarly in the DMS task, there was a significant effect of delay (assumption of sphericity was not met, Greenhouse-Geisser 1.377, 8.265 = 10.621, P = 0.008) (Fig. 3b) . At 30-second delays for the DR task and 120-second As expected, cognitive performance decreased as delay intervals increased, with performance at a delay of 15 seconds being considered a true measure of memory in the DR task and performance a delay of 120 seconds a true measure of memory in the DMS task. Each bar represents the mean of eight animals and the vertical lines represent SEMs. Values with different letters were significantly different (P < 0.01), except for the difference in DMS performance at 60-and 120-second delays (P < 0.05; ANOVA followed by the Newman-Keuls test). delays for the DMS task, the animals appeared to be at their cognitive limits, achieving scores of only ∼50% correct. Figure 4a shows cognitive performance (at each delay in the DR task) observed at the end of the DHEA administration period, expressed as a percentage of baseline performance. For reference, it also shows cognitive performance at the end of the untreated period (see Fig. 2 for schematic representation of the cognitive testing timeline). Values greater than 100% indicate an improvement in performance across each of the two 3-month testing phases; this shows a practice effect on performance and validates the normalization of the results relative to baseline performance at the beginning of each testing phase. A repeated-measures ANOVA showed no significant effect of delay (P > 0.05), no significant effect of treatment (P > 0.05) and no significant delay × treatment interaction (P > 0.05). Thus, DHEA supplementation did not affect change in performance over time in this task. Figure 4b shows cognitive performance (at each delay in the DMS task) observed at the end of the DHEA Figure 5 : Correlation of cognitive performance with steroidogenic and steroid-related gene expression in the HPC and PFC of aged female rhesus macaques. Animals were ranked by their score in the final off-DHEA battery on the 15-second delay in the DR task and the 60-second delay in the DMS task. These ranks were then correlated with relative gene expression using Kendall's b. Only significant correlations are presented. See Table 1 and text for details of the statistical analysis definition of gene names. administration period, expressed as a percentage of baseline performance. For reference, it also shows cognitive performance at the end of the untreated period. Similar to the DR task, there was no significant effect on change in performance of treatment (P > 0.05) or delay (P > 0.05), nor was there any significant delay × treatment interaction (P > 0.05).
Correlations between cognitive performance and steroid-related gene expression
Correlations between rank-ordered cognitive data and gene expression data in the HPC and PFC are depicted in Fig. 5 and the results of the corresponding Kendall's b statistical analyses are shown in Table 1 . In the HPC, better cognitive performance in the DMS task was correlated with lower levels of expression of HSD11B1 (the gene encoding 11 -hydroxysteroid dehydrogenase, the enzyme that synthesizes cortisol from cortisone) and NR3C1 (glucocorticoid receptor). Better cognitive performance in the DR task was associated with higher levels of expression of AKR1C3 (also known as HSD17B5, the enzyme that converts E 1 into E 2 ) and STAR (steroidogenic acute regulatory protein, the first protein necessary for synthesis of steroids from cholesterol) and with lower levels of SRD5A1 [5 -reductase type 1, the enzyme synthesizing 5 dihydrotestosterone (5 DHT) from testosterone]. In the PFC, better performance in the DMS task was correlated with higher levels of expression of AKR1C3 and with lower levels of expression of STAR.
Discussion
Evidence for interaction between the hypothalamicpituitary-adrenal and hypothalamic-pituitary-gonadal axes in perimenopausal women (Crawford et al. 2009; Pluchino et al. 2005) suggests compensation between circulating E 2 and DHEAS; however, the effect of supplemental DHEA or DHEAS on circulating E 2 is unclear, with studies showing gradual increases or no effect (Caufriez et al. 2013; Labrie et al. 2007 Labrie et al. , 2008 ). In the current study, we hypothesized that DHEA supplementation in perimenopausal rhesus macaques would increase central levels of E 2 and thereby result in significant improvement of cognitive performance. This hypothesis was tested using aged female rhesus macaques as they were approaching their menopausal years, but before they had experienced extreme attenuation of their circulating E 2 levels. The rationale for this experimental design stemmed from reports that cognitive function is enhanced in women undergoing estrogen replacement therapy when the treatment is initiated close to the time of menopause (Shao et al. 2012) , but not when the treatment is significantly delayed (Espeland et al. 2004; Rapp et al. 2003b) . Based on our previous observation that circulating DHEAS levels are already significantly attenuated before the onset of menopause (Sorwell et al. 2012) , we expected to observe a significant improvement of cognitive performance after ∼2.5 months of supplementary DHEA; however, supplementation had no significant effect on either DR or DMS performance. Consequently, our results are consistent with the earlier negative findings by Herndon et al. (1999) , which failed to show a correlation between DHEAS and cognitive performance in rhesus macaques. There are many possible reasons for the lack of obvious pro-cognitive effects of DHEA in humans and nonhuman primates. First, the duration of the DHEA treatment in the current study may have been too short to elicit a significant effect, although previously we observed cognitive improvements in ovariectomized macaques after only 2 months of treatment with E 2 (Kohama et al. 2016) . It is also possible that the 5-mg oral dose of DHEA we administered daily was suboptimal at maintaining elevated circulating levels of DHEAS throughout the entire day . Another possible cause for the negative results is that our old females were still able to maintain elevated E 2 levels in their cognitive brain centers, despite showing perimenopausal hormonal changes in the circulation. It may be, therefore, that pro-cognitive effects of supplementary hormones only become evident when the endogenous levels of estrogens in the brain are significantly reduced, which might not occur in rhesus macaques until after the animals have completely transitioned into menopause and/or after ovariectomy. While this does not rule out effects of the more complete loss of ovarian steroids seen in post-menopause, it does suggest that the cognitive deficits associated with menopause in aged female macaques occur later in the reproductive life span than examined in the current study.
Additionally, from a cognitive perspective, ∼2.5 months of testing may not have been sufficient time to show a deviation in the rate of improvement in these animals. All animals were required to meet testing criteria prior to the beginning of the study, resulting in significant selection bias, as those aged females showing significant cognitive deficits were excluded from participation in this experiment. Therefore, all animals included in the study were successful 'cognitive agers', and may have been less likely to show cognitive decline over such a short (<1 year) period of time.
Although our experimental design was aimed at an earlier intervention than is typically used in humans, in order to avoid an extended period of E 2 deprivation, this design may have inadvertently resulted in the opposite effect: any cognitive impact of low DHEA levels may have been masked by the maintained E 2 levels in these animals. Thus, a ceiling effect may have been reached by the endogenous circulating E 2 , making any additional locally synthesized E 2 resulting from the DHEA supplementation superfluous, as animals may have already been performing at maximal levels.
We also observed no significant increase in circulating E 2 with DHEA supplementation, contrary to what we expected according to the hypothesis that DHEA is a significant source of active estrogens. Our prediction was that levels of E 2 would increase, as DHEA is a precursor of E 2 ; however, this lack of change in circulating E 2 does not necessarily indicate that E 2 levels within various peripheral tissues were not increased by the treatment. Labrie et al. (1998) have estimated that in premenopausal women, roughly 75% of active estrogens in tissues are produced locally; thus, a detailed analysis of E 2 concentrations in multiple tissues on and off DHEA treatment would be necessary to assess the true effect of DHEA supplementation on E 2 exposure. As this experiment was a within-subject design, it was not feasible to perform these analyses in the current study. Additionally, circulating DHEA and E 2 have been shown to be inversely correlated during the menopausal transition and estrogen supplementation (Crawford et al. 2009; Pluchino et al. 2005) . Thus, ovarian E 2 may be downregulated by an increase in E 2 derived from exogenous DHEA.
The results of correlations between cognitive performance and central gene expression provide insights into the potential roles of steroidogenic and steroid-related genes in cognition. In the HPC, performance in the DMS task was negatively correlated with HSD11B1, suggesting that the local action of this enzyme in the conversion of cortisone to cortisol may negatively impact cognition. Although no direct evidence of central cortisol production in the nonhuman primate has yet been published, studies of aging and memory in mice have observed a significant negative impact of central corticosterone production on memory and have noted that the expression of HSD11B1 is associated with greater cognitive impairment (Holmes & Seckl 2006; Holmes et al. 2010) . It has also been shown that inhibition or knockout of HSD11B1 helps to maintain spatial memory during aging to a greater extent than in wild-type controls (Sooy et al. 2010; Yau et al. 2007) . Furthermore, this mechanism is thought to involve increased activation of mineralocorticoid receptors rather than glucocorticoid receptors (Yau et al. 2011) . Consistent with this previous report, we found the expression of the glucocorticoid receptor (NR3C1) to be negatively correlated with cognitive performance in our old monkeys. Taken together, therefore, our findings give support to the idea that these two genes work in concert to protect the HPC from stress-induced memory impairments and that individuals retaining the ability to downregulate their glucocorticoid receptors during aging are more resistant to cognitive deficits induced by stress and hypercortisolemia (McEwen 2002) .
Also of note was the significant positive correlation between expression of AKR1C3 (the gene encoding HSD17B5) in the HPC and better cognitive performance in the DR task, as well as the significant positive correlation between the expression of AKR1C3 in the PFC and better cognitive performance in the DMS task. The AKR1C3 enzyme plays a key role in the de novo synthesis of sex steroids in the brain by participating in the metabolism of DHEA into testosterone and/or E 1 into E 2 . Given that E 2 has known cognitive benefits in monkeys, the observed positive correlations are not surprising. On the other hand, it is unclear whether testosterone itself can directly affect cognitive function or whether its influence is mediated by its two primary bioactive metabolites E 2 and 5 DHT. However, higher expression of enzymes that promote the local production of E 2 appear to enhance memory performance, whereas higher levels of SRD5A1 (encoding 5 -reductase type 1, an enzyme that converts testosterone to 5 DHT) appear to be associated with worse performance. Thus, a decrease in the expression of SRD5A1 would allow more testosterone to be aromatized to E 2 rather than being converted to 5 DHT. If true, this would suggest that during aging pro-cognitive effects of sex steroids may ultimately be mediated by estrogen receptors rather than androgen receptors. Interestingly, STAR, which encodes the steroid acute regulatory protein and represents a rate limiting gene in the de novo synthesis of steroids, showed a significant positive correlation between its expression in the HPC and better cognitive performance in the DR task, but showed a significant negative correlation between its expression in the PFC and better cognitive performance in the DMS task. The reason for these two radically different STAR expression patterns is unclear. However, we have previously observed that key genes involved in the conversion of DHEA to E 2 (e.g. 3BHSD1/2 and AKR1C3) are more highly expressed in the rhesus macaque PFC than in the HPC (Sorwell et al. 2012) . Consequently, it is plausible that attenuated expression of STAR helps to protect the PFC from excessive steroid levels by moderating de novo synthesis.
Taken together, these data suggest that modulation of local steroid synthesis may play an important role in maintaining cognitive function in aged female macaques and may explain why no further enhancement of cognitive function was observed after DHEA supplementation.
